Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study

INTRODUCTION: Von Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures or bleeding, patients are treated with desmopressin and/or VWF-containing concentrates to increase plasma VWF and factor VIII (FVIII). How...

Descripción completa

Detalles Bibliográficos
Autores principales: Heijdra, Jessica M, Al Arashi, Wala, de Jager, Nico C B, Cloesmeijer, Michael E, Bukkems, Laura H, Zwaan, Christian M, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852670/
https://www.ncbi.nlm.nih.gov/pubmed/35168962
http://dx.doi.org/10.1136/bmjopen-2021-049493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852670/
https://www.ncbi.nlm.nih.gov/pubmed/35168962
http://dx.doi.org/10.1136/bmjopen-2021-049493

Ejemplares similares